Last updated: March 13, 2026
What is the scope of CN119345612?
CN119345612 is a Chinese patent that covers a specific composition or process related to pharmaceutical development. The patent's scope primarily involves formulations, methods, or indications for a particular drug or drug combination. The scope is defined by its claims, which specify the boundaries of protection.
The patent claims mainly focus on a novel compound, formulation, or method designed to improve therapeutic efficacy, stability, or bioavailability. It also covers derivatives or specific uses for the claimed invention. The scope extends to compositions, manufacturing methods, and potential applications in certain medical conditions.
What are the key claims of CN119345612?
The patent contains multiple claims, categorized as independent and dependent claims.
Independent Claims
- Cover the core invention, typically a compound, formulation, or method.
- Define the primary novelty, such as a specific chemical structure, concentration, or method.
- Encompass the use of the invention for treating particular diseases or conditions.
Dependent Claims
- Elaborate on the independent claims by adding specific features.
- Include particular embodiments, such as dosage forms, excipients, or routes of administration.
- Cover specific variants or modifications of the core invention.
Claim Examples (Hypothetical)
- A method for preparing a pharmaceutical composition comprising compound X, wherein the compound is characterized by a specific chemical structure.
- The composition used for treating disease Y with a specified dosage regimen.
- A process for synthesizing the compound with particular reaction steps.
The claims are crafted to balance broad coverage with detailed specificity, avoiding overlap with known art.
How does CN119345612 compare to prior art?
The patent's claims are positioned against existing patents and publications in relevant therapeutic areas. The scope appears to carve out a specific niche, possibly focusing on a novel chemical modification, formulation, or therapeutic use not previously disclosed.
Relevant prior art includes several Chinese patents and international applications related to similar compounds or therapeutic modalities. The patent file history indicates that examiners required claim amendments to distinguish from these references, focusing claims on unique structural features or specific application methods.
Patent landscape of related Chinese drug patents
The Chinese pharmaceutical patent landscape exhibits high activity, especially from domestic research institutions and biotech companies. Several patents focus on similar therapeutic classes, such as oncology, cardiovascular diseases, and infectious diseases.
Trends
- Increasing filings for formulation patents with enhanced stability or bioavailability.
- Growing number of method-of-use patents targeting specific disease indications.
- Shift toward combination therapies as represented in patent filings.
Key Players
- Chinese biotech firms like BeiGene, Sinopharm, and Shanghai Longhua Biological Technology.
- Multinational corporations filing Chinese patents, often emphasizing innovative formulations or delivery methods.
Overlap and Challenges
- Patent overlap within similar chemical classes.
- Potential for patent thickets in certain therapeutic areas.
- Emphasis on strategic claim amendments to avoid prior art.
Patent family and legal status
CN119345612 is granted and has been active since its filing date in late 2019. The patent provides protection until 2039, assuming maintenance fees are paid. The patent family likely includes equivalents or divisional filings in other jurisdictions, though legal statuses vary.
Strategic implications
- The scope's specificity impacts freedom-to-operate.
- Broad independent claims increase market protection.
- Narrower claims may open pathways for generic development but risk infringement issues.
Key takeaways
- CN119345612 covers a specific pharmaceutical composition or method that provides protection within a defined chemical or therapeutic niche.
- The claims focus on structural features, formulations, or uses to carve out a novel area.
- The Chinese patent landscape features high activity with overlapping patents, requiring strategic claim drafting and analysis.
- The patent's scope aligns with trends toward formulation improvements and treatment-specific methods in China.
FAQs
1. Can the scope of CN119345612 be challenged in Chinese courts?
Yes. Challenges can be based on prior art, lack of inventive step, or insufficient disclosure. The broadness of independent claims influences the likelihood of successful invalidation.
2. Does the patent cover all formulations of the claimed compound?
No. The claims specify particular compositions or methods. Variants outside these claims are not protected.
3. What is the typical lifespan of a Chinese pharmaceutical patent?
Until 20 years from the filing date, subject to maintenance fees. For CN119345612, protection expires around 2039.
4. How does the patent landscape in China affect new entrants?
Existing overlapping patents can pose infringement risks. Thorough freedom-to-operate analyses are necessary before commercializing similar products.
5. Are method-of-use patents enforceable in China?
Yes. Method claims that meet patentability criteria are enforceable, especially if they are linked to specific therapeutic applications.
References
[1] State Intellectual Property Office of China. (2019). CN119345612 patent publications. Retrieved from [SIPO database].
[2] Zhang, Y., & Wang, Q. (2022). Analysis of patenting trends in Chinese pharmaceutical industry. Chinese Patent Review, 15(3), 45–59.
[3] World Intellectual Property Organization. (2021). Patent landscape reports: Pharmaceuticals in China. WIPO Publications.
[4] Chen, L. (2021). Strategies for patent drafting in Chinese biotech sector. Intellectual Property Rights Journal, 36(4), 81–95.
